Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose infliximab (TA-650) in rheumatoid arthritis on background methotrexate
jRCT2080220144Phase 3
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Oct 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of infliximab in rheumatoid arthritis (RA), sponsored by Mitsubishi Tanabe Pharma Corporation.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080220144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220144.